MDVN

24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
In one of the longest running bidding wars in recent times, Pfizer has finally reeled in cancer-drug maker Medivation.
Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what price.
France-based Sanofi has been pursuing Medivation, but the company has been reluctant in responding to these offers. However things could be changing.
Usually the term "hostile takeover" is an exaggeration, but Sanofi's takeover bid for Medivation actually looks pretty hostile, given that it is now trying to oust the entire board.
One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation found itself in.
Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy that should come in fine when numbers are released.
Tuesday's top analyst initiations, upgrades and downgrades include Devon Energy, Illumina, Pandora, Panera Bread, Potash, Regions Financial and Southwestern Energy.
The top analyst upgrades, downgrades and initiations seen this Wednesday morning include Apple, AIG, Medivation, PayPal, Shake Shack and TerraForm Power.
The top analyst upgrades, downgrades and initiations seen on Friday, February 19, include Applied Materials, Duke Energy, Entergy, Salesforce,com and SunEdison.
Medivation, Inc. (NASDAQ: MDVN) was not having a great day on Wednesday. Its shares were seen down 5% or so at $33.10 shortly before the close. News was out on Tuesday signaling that the Journal of...
One interesting tidbit to this week's insider trading was all the energy stocks that are showing up. It is clear many insiders feel the bottom is close and now is the time to buy shares.